ArticleBlood2017

Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma.

Sophia Gayle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.